William Blair analyst Raju Prasad upgraded PTC Therapeutics (NASDAQ: PTCT) to Buy today. The company’s shares opened today at $38.29.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 19.3% and a 59.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Audentes Therapeutics.
Currently, the analyst consensus on PTC Therapeutics is a Moderate Buy with an average price target of $46, a 20.1% upside from current levels. In a report issued on July 24, Citigroup also maintained a Buy rating on the stock with a $50 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.95 and a one-year low of $14.56. Currently, PTC Therapeutics has an average volume of 1.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology.
